Gastrointestinal contractility will be studied in healthy volunteers for 7 hours in a fasting condition
Conditions
Interventions
Trade Name: Erythrocine
Pharmaceutical Form: Powder for solution for injection/infusion
INN or Proposed INN: ERYTHROMYCIN LACTOBIONATE
CAS Number: 3847-29-8
Concentration unit: mg/ml milligram(s)/mill
Sponsors
UZLeuven
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: °Female or male subjects aged 18 to 60 °Subject is capable and willing to give informed consent °Female volunteers of child bearing potential must use oral, injected or implanted hormonal methods of contraception Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 15 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: °Female volunteer is pregnant or breastfeeding °Gastrointestinal diseases, major abdominal surgery °Major psychiatirc illnesses °Volunteers that use drugs affecting the gastrointestinal tract or the central nervous system °Allergy for macrolide antibiotics °Allergy for atropine °Severe heartburn °Enlarged prostate °Blockage of urinary tract °Acute closed-angle glaucoma °Myasthenia gravies °Severe heart disease °Thyrotoxicosis °Fever °Liver problems °High blood pressure or fast heart rate °Lung disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Investigating if contractions are necessary to induce hunger feelings, or if erythromycin has a secundary effect ;Secondary Objective: NA;Primary end point(s): Motility will be recorded for 7 hours;Timepoint(s) of evaluation of this end point: end of trial | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): NA;Timepoint(s) of evaluation of this end point: NA | — |
Countries
Belgium
Contacts
Public ContactJan Tack
UZLeuven
Outcome results
None listed